Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2026
Acquired Blepharoptosis for the Dermatologic Surgeon: Recognition, Assessment, and Nonsurgical Management.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fathizadeh Sam, Aitkens Lorry E, Sherman Deborah D, Carruthers Jean, Hooper Deirdre
Аннотация
BACKGROUND: Blepharoptosis, or drooping of the upper eyelid, is commonly encountered by dermatologic surgeons due to aging, medical conditions, periocular procedures, and/or inadvertent neurotoxin administration. Proper recognition and management are critical for both functional and cosmetic outcomes.
OBJECTIVE: To review clinically relevant anatomy, diagnostic evaluation, and nonsurgical treatments for acquired ptosis, emphasizing considerations specific to dermatologic practice.
MATERIALS AND METHODS: A literature review of PubMed and Embase identified English-language studies and clinical trials addressing the diagnosis and management of blepharoptosis, with emphasis on nonsurgical and dermatologic applications.
RESULTS: Key diagnostic tools include the marginal reflex distance 1, levator function testing, and standardized preprocedure and postprocedure photography. Oxymetazoline 0.1% demonstrates modest but statistically significant improvement in marginal reflex distance 1 and superior visual field improvement in randomized trials. Off-label adrenergic agents and targeted pretarsal botulinum toxin injections may offer adjunctive benefits, although supporting evidence is limited.
CONCLUSION: Dermatologic surgeons are positioned to identify and manage mild acquired ptosis using validated metrics and nonsurgical options. Selective botulinum toxin placement can be considered in selected cases; supporting evidence remains limited. Appropriately identifying cases that need referral for surgical repair will also benefit patient care by improving vision, daily function, and cosmesis.
OBJECTIVE: To review clinically relevant anatomy, diagnostic evaluation, and nonsurgical treatments for acquired ptosis, emphasizing considerations specific to dermatologic practice.
MATERIALS AND METHODS: A literature review of PubMed and Embase identified English-language studies and clinical trials addressing the diagnosis and management of blepharoptosis, with emphasis on nonsurgical and dermatologic applications.
RESULTS: Key diagnostic tools include the marginal reflex distance 1, levator function testing, and standardized preprocedure and postprocedure photography. Oxymetazoline 0.1% demonstrates modest but statistically significant improvement in marginal reflex distance 1 and superior visual field improvement in randomized trials. Off-label adrenergic agents and targeted pretarsal botulinum toxin injections may offer adjunctive benefits, although supporting evidence is limited.
CONCLUSION: Dermatologic surgeons are positioned to identify and manage mild acquired ptosis using validated metrics and nonsurgical options. Selective botulinum toxin placement can be considered in selected cases; supporting evidence remains limited. Appropriately identifying cases that need referral for surgical repair will also benefit patient care by improving vision, daily function, and cosmesis.